Definitive Chemoradiation for Oesophageal Cancer - A Standard of Care in Patients with Non-metastatic Oesophageal Cancer

Gwynne, Sarah Helene, Hurt, Chris Nicholas ORCID: https://orcid.org/0000-0003-1206-8355, Evans, M., Holden, C., Vout, Lauren and Crosby, Thomas David Lewis 2011. Definitive Chemoradiation for Oesophageal Cancer - A Standard of Care in Patients with Non-metastatic Oesophageal Cancer. Clinical Oncology 23 (3) , pp. 182-188. 10.1016/j.clon.2010.12.001

Full text not available from this repository.

Abstract

AIMS: A retrospective analysis was carried out of 291 cases of oesophageal cancer treated with definitive chemoradiotherapy (dCRT) at a single UK cancer centre between 1995 and 2009. Our protocol consisted of two cycles of neoadjuvant platinum-based chemotherapy followed by two further cycles given concurrently with 50Gy of external beam radiotherapy delivered in 25 fractions over 5 weeks. MATERIALS AND METHODS: Demographic, patient and outcome data were recorded prospectively through an electronic health record and retrospectively analysed, using appropriate statistical tools. RESULTS: Data on 266 patients were available for analysis. The median age was 66.6 years, 53% were adenocarcinomas. dCRT was used instead of surgery because of age/co-morbidity in 44% and disease extent in 39%. Ninety-three per cent of patients completed treatment according to protocol. Grade 3 and 4 toxicities were seen in 42 and 7%, respectively. Median survival was 20.6 months; 2, 3 and 5 year survival rates were 43.6, 32.9 and 19.5%, respectively. Advanced disease was associated with a worse outcome. Shorter disease length was associated with a better median survival, but some patients with disease >10cm had long-term disease control. The effect of other patient- and disease-related factors was also analysed. CONCLUSION: We present data showing that dCRT is well tolerated and should be considered as an alternative to surgery for all patients with locally advanced oesophageal cancer, not only those with co-morbidity. Furthermore, the benefits of dCRT are not confined to carcinomas with squamous histology.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Postgraduate Medical and Dental Education
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Elsevier
ISSN:	0936-6555
Last Modified:	19 Oct 2022 10:25
URI:	https://orca.cardiff.ac.uk/id/eprint/24305

Citation Data

Cited 83 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item